Cure8 news brief
This mid‑stage trial reports strong week‑44 clinical remission and endoscopic response rates for duvakitug, an investigational anti‑TL1A therapy, in both UC and Crohn’s disease — a development that could expand future treatment options if later‑stage trials and regulators confirm benefit and safety.
Adults with moderate‑to‑severe UC or Crohn’s disease, patients tracking new biologic/small‑molecule therapies, clinicians treating IBD, and researchers interested in anti‑TL1A mechanisms or drug development.
Sanofi and Teva reported Phase IIb RELIEVE UCCD (NCT05668013) results for duvakitug, an investigational anti‑TL1A therapy studied in moderate‑to‑severe ulcerative colitis and Crohn’s disease.
The trial randomized 247 patients to 450 mg or 900 mg every four weeks and presented week‑44 maintenance outcomes, including clinical remission and endoscopic response rates in the high‑dose arm. Safety during the maintenance period showed no new signals, with discontinuations for adverse events reported between 2–6% depending on indication.
This article summarizes a mid‑stage trial readout presented by Clinical Trials Arena (Yahoo! Finance syndication). It focuses on efficacy (clinical remission, clinical response, endoscopic improvement) and tolerability of duvakitug through week 44, and places the result in the context of other anti‑TL1A programs and recent industry deals.
If you are following emerging IBD therapies, these Phase IIb results are encouraging but do not change clinical practice until confirmed in Phase III trials and regulatory review. Whether benefits persist long term, how the drug compares head‑to‑head with existing options, and final safety findings will matter for future use.
These are Phase IIb results reported in a news article summarizing the trial; Phase III trials and regulatory review are still needed before this drug could become an approved treatment. The report comes from Clinical Trials Arena via Yahoo! Finance and references trial identifier NCT05668013.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...
The study suggests a hidden, early molecular defect that leaves intestinal cells primed to die even during clinical remission, which could help explain why flares recur. Measuring these molecular signals might eventually...
